Oncolytics Biotech Inc T.ONC

Opposing Oncolytic Virus companies share prices

[Noteable]

Candel Therapeutics -> US$14.00 a/0 May 15, 2024 

CG Oncology -> US$28.01 a/0 May 15, 2024 

[Noteable]

Corresponding Market Caps: Phase 1 Candel Therapeutics -> US$410 Million Phase 2/3 CG Oncology -> US$1.87 Billion

[Noteable]

Meanwhile ONCY is aligned with Canaccord Genuity and Anson Funds Management 

[Noteable]

If ONCY knew about its pending relationship with CGAR, as Matt Coffey keeps implying, then why didn't they get better funding arrangements? Now Coffey says that ONCY "  has entered into a preliminary collaboration with the Global Coalition for Adaptive Research (GCAR)." "The purpose of the preliminary collaboration is to commence planning activities for the

[Noteable]

As of March 31, 2024 Anson Funds Management sold out its entire holdings in ONCY, yet still holds its options on warrants that they received in their announced August 08, 2023 funding. https://www.nasdaq.com/market-activity/stocks/oncy/institutional-holdings?page=3&rows_per_page=10 https://oncolyticsbiotech.com/press_releases/oncolytics-biotech-successfully-raises-us15-million-to-advance

[lonc17]

Too funny. Some posters still believe that Anson was a major shareholder. Ten minutes of research and you will learn that Anson very likely sold ONC short leading into the financing. IMO ONC allowed Anson to cover their short by selling them the five million newly minted shares. Just like the monthly ATM but many times more destructive to shareholder value. For which MC and Kirk should have

[Noteable]

Political developments including higher short interest costs and Anson Funds Managment need for raise immediate cash for their bail-out funding of DWAC and the continuation of 'Truth Social" under the formation of Donald Trump's company DJT, Anson Funds would have had to covered its short postion with its own shares, which appears to have resulted in their selling out of ONCY. https:

[Noteable]

Should read: " ... Anson Funds Managment need for an immediate cash raise for their bail-out funding of DWAC ..."

[lonc17]

Do you believe what you post Notable, or is it simply to make us laugh? Because your latest post is actually quite funny.

[Noteable]

" Investment firms Anson Funds, All Blue Capital and Mangrove Partners have offered to buy the convertible notes on offer, the sources added, cautioning that the timing and composition of the deal may still change.  The sources requested anonymity because details of the deal discussions are confidential. DWAC Chief Executive Eric Swider declined to comment. Representatives for

[Noteable]

https://stockhouse.com/companies/bullboard/c.huge/fsd-pharma-inc?postid=35380327

[Noteable]

CG Oncology -> US$33.01 per share a/o May 24, 2024   Today announced final results from the Phase 2 CORE-001 clinical trial of its intravessically delivereed (liquid treatment that is put directly into the bladder through a catheter) ) oncolytic virus immunotherapy candidate, cretostimogene, in combination with pembrolizumab for the treatment of BCG-Unresponsive, High-Risk Non

[Noteable]

CG Oncology -> Market Cap US$2.20 Billion a/o May 24, 2024 <- for a Phase 2 OV company.